{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:01:10Z","timestamp":1778842870538,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Dysregulation of epidermal growth factor and insulin-like growth factor signaling play important roles in human hepatocellular carcinoma (HCC), leading to frequent activation of their downstream targets, the ras\/raf\/extracellular signal-regulated kinase (ERK) and the phosphoinositide 3-kinase (PI3K)\/Akt\/mammalian Target of Rapamycin (mTOR) pathways. Salirasib is an S-prenyl-cysteine analog that has been shown to block ras and\/or mTOR activation in several non hepatic tumor cell lines. We investigated <jats:italic>in vitro<\/jats:italic> the effect of salirasib on cell growth as well as its mechanism of action in human hepatoma cell lines (HepG2, Huh7, and Hep3B) and its <jats:italic>in vivo<\/jats:italic> effect in a subcutaneous xenograft model with HepG2 cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Salirasib induced a time and dose dependent growth inhibition in hepatocarcinoma cells through inhibition of proliferation and partially through induction of apoptosis. A 50 percent reduction in cell growth was obtained in all three cell lines at a dose of 150 \u03bcM when they were cultured with serum. By contrast, salirasib was more potent at reducing cell growth after stimulation with EGF or IGF2 under serum-free conditions, with an IC<jats:sub>50<\/jats:sub> ranging from 60 \u03bcM to 85 \u03bcM. The drug-induced anti-proliferative effect was associated with downregulation of cyclin A and to a lesser extent of cyclin D1, and upregulation of p21 and p27. Apoptosis induction was related to a global pro-apoptotic balance with caspase 3 activation, cytochrome c release, death receptor upregulation, and a reduced mRNA expression of the apoptosis inhibitors cFLIP and survivin. These effects were associated with ras downregulation and mTOR inhibition, without reduction of ERK and Akt activation. <jats:italic>In vivo<\/jats:italic>, salirasib reduced tumour growth from day 5 onwards. After 12 days of treatment, mean tumor weight was diminished by 56 percent in the treated animals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results show for the first time that salirasib inhibits the growth of human hepatoma cell lines through inhibition of proliferation and induction of apoptosis, which is associated with ras and mTOR inhibition. The therapeutic potential of salirasib in human HCC was further confirmed in a subcutaneous xenograft model.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-9-256","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T18:15:09Z","timestamp":1285179309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition"],"prefix":"10.1186","volume":"9","author":[{"given":"Nicolas","family":"Charette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"De Saeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Lannoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"St\u00e4rkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,22]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053\/j.gastro.2007.04.061","journal-title":"Gastroenterology"},{"issue":"Supplement7","key":"771_CR2","first-page":"vii1","volume":"20","author":"C Verslype","year":"2008","unstructured":"Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C: The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th world congress on gastrointestinal cancer, Barcelona, 2008. Ann Oncol. 2008, 20 (Supplement7): vii1-vii6.","journal-title":"Ann Oncol"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1038\/sj.onc.1209556","volume":"25","author":"K Breuhahn","year":"2006","unstructured":"Breuhahn K, Longerich T, Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006, 25: 3787-3800. 10.1038\/sj.onc.1209556","journal-title":"Oncogene"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1349-7006.2008.01006.x","volume":"100","author":"S Tanaka","year":"2009","unstructured":"Tanaka S, Arii S: Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009, 100: 1-8. 10.1111\/j.1349-7006.2008.01006.x","journal-title":"Cancer Sci"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.1158\/0008-5472.CAN-07-6720","volume":"68","author":"E Buck","year":"2008","unstructured":"Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS: Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68: 8322-8332. 10.1158\/0008-5472.CAN-07-6720","journal-title":"Cancer Res"},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.20538","volume":"41","author":"E Schiffer","year":"2005","unstructured":"Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005, 41: 307-314. 10.1002\/hep.20538","journal-title":"Hepatology"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008, 9: 517-531. 10.1038\/nrm2438","journal-title":"Nat Rev Mol Cell Biol"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","volume":"14","author":"MM Chitnis","year":"2008","unstructured":"Chitnis MM, Yuen JSP, Protheroe AS, Pollak M, Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008, 14: 6364-6370. 10.1158\/1078-0432.CCR-07-4879","journal-title":"Clin Cancer Res"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1172\/JCI31457","volume":"117","author":"DF Calvisi","year":"2007","unstructured":"Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007, 117: 2713-2722. 10.1172\/JCI31457","journal-title":"J Clin Invest"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","volume":"135","author":"A Villanueva","year":"2008","unstructured":"Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008, 135: 1972-1983. 10.1053\/j.gastro.2008.08.008","journal-title":"Gastroenterology"},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","volume":"270","author":"M Marom","year":"1995","unstructured":"Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y: Selective inhibition of ras-dependent cell growth by farnesylthiosalicylic acid. J Biol Chem. 1995, 270: 22263-22270. 10.1074\/jbc.270.38.22263","journal-title":"J Biol Chem"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/bi972032d","volume":"37","author":"R Haklai","year":"1998","unstructured":"Haklai R, Gana Weisz M, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y: Dislodgment and accelerated degradation of ras. Biochemistry. 1998, 37: 1306-1314. 10.1021\/bi972032d","journal-title":"Biochemistry"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1210\/me.2004-0305","volume":"19","author":"LP McMahon","year":"2005","unstructured":"McMahon LP, Yue W, Santen RJ, Lawrence JC: Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol. 2005, 19: 175-183. 10.1210\/me.2004-0305","journal-title":"Mol Endocrinol"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-06-4287","volume":"67","author":"R Blum","year":"2007","unstructured":"Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y: Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007, 67: 3320-3328. 10.1158\/0008-5472.CAN-06-4287","journal-title":"Cancer Res"},{"key":"771_CR16","volume-title":"Cancer Chemother Pharmacol","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R: Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid in patients with solid tumors. Cancer Chemother Pharmacol. 2009, ,"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/CS20070152","volume":"114","author":"A Da Silva Morais","year":"2008","unstructured":"Da Silva Morais A, Saliez A, Leclercq I, Horsmans Y, Starkel P: Inhibition of the ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci (London). 2008, 114: 73-83. 10.1042\/CS20070152.","journal-title":"Clin Sci (London)"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.ejca.2009.04.014","volume":"45","author":"T Schneider-Merck","year":"2009","unstructured":"Schneider-Merck T, Borbath I, Charette N, De Saeger C, Abarca J, Leclercq I, Horsmans Y, Starkel P: The ras inhibitor Farnesylthiosalicylic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer. 2009, 45: 2050-2060. 10.1016\/j.ejca.2009.04.014","journal-title":"Eur J Cancer"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods. 2001, 25: 402-408. 10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1038\/sj.onc.1201105","volume":"14","author":"J Fan","year":"1997","unstructured":"Fan J, Bertino JR: K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997, 14: 2595-2607. 10.1038\/sj.onc.1201105","journal-title":"Oncogene"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cellsig.2004.04.003","volume":"16","author":"J Halaschek-Wiener","year":"2004","unstructured":"Halaschek-Wiener J, Wachek V, Kloog Y, Jansen B: Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal. 2004, 16: 1319-1327. 10.1016\/j.cellsig.2004.04.003","journal-title":"Cell Signal"},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrm1496","volume":"5","author":"SJ Riedl","year":"2004","unstructured":"Riedl SJ, Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004, 5: 897-907. 10.1038\/nrm1496","journal-title":"Nat Rev Mol Cell Biol"},{"key":"771_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep.21812","volume":"46","author":"JL Mott","year":"2007","unstructured":"Mott JL, Gores GJ: Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology. 2007, 46: 906-911. 10.1002\/hep.21812","journal-title":"Hepatology"},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006, 5: 671-688. 10.1038\/nrd2062","journal-title":"Nat Rev Drug Discov"},{"key":"771_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood-2002-01-0189","volume":"101","author":"T Decker","year":"2003","unstructured":"Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2003, 101: 278-285. 10.1182\/blood-2002-01-0189","journal-title":"Blood"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1535-7163.MCT-06-0193","volume":"5","author":"R Blum","year":"2006","unstructured":"Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y: Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther. 2006, 5: 2337-2347. 10.1158\/1535-7163.MCT-06-0193","journal-title":"Mol Cancer Ther"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.1158\/0008-5472.CAN-06-4762","volume":"67","author":"B Pan","year":"2007","unstructured":"Pan B, Cui D, Sheng Y, Ozkan C, Cao F, He R, Li Q, Xu P, Huang T: Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007, 67: 8156-8163. 10.1158\/0008-5472.CAN-06-4762","journal-title":"Cancer Res"},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3748\/wjg.v11.i2.193","volume":"11","author":"DJ Dai","year":"2005","unstructured":"Dai DJ, Lu CD, Lai RY, Guo JM, Meng H, Chen WS, Gu J: Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol. 2005, 11: 193-199.","journal-title":"World J Gastroenterol"},{"key":"771_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/00042737-200107000-00005","volume":"13","author":"M Schuschmann","year":"2001","unstructured":"Schuschmann M, Galle PR: Apoptosis in liver disease. Eur J Gastroenterol Hepatol. 2001, 13: 785-790. 10.1097\/00042737-200107000-00005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1074\/jbc.M604953200","volume":"282","author":"M Malml\u00f6f","year":"2007","unstructured":"Malml\u00f6f M, Roudier E, H\u00f6gberg J, Stenius Ulla: MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. J Biol Chem. 2007, 282: 2288-2296. 10.1074\/jbc.M604953200","journal-title":"J Biol Chem"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/hep.22915","volume":"50","author":"A Gonzalez-Rodriguez","year":"2009","unstructured":"Gonzalez-Rodriguez A, Alba J, Zimmerman V, Kozma SC, Valverde A: S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology. 2009, 50: 216-229. 10.1002\/hep.22915","journal-title":"Hepatology"},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0168-8278(99)80318-3","volume":"31","author":"S Reif","year":"1999","unstructured":"Reif S, Weis B, Aeed H, Gana-Weis M, Zaidel L, Avni Y, Romanelli RG, Pinzani M, Kloog Y, Bruck R: The ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol. 1999, 31: 1053-1061. 10.1016\/S0168-8278(99)80318-3","journal-title":"J Hepatol"},{"key":"771_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jhep.2004.04.010","volume":"41","author":"S Reif","year":"2004","unstructured":"Reif S, Aeed H, Shilo Y, Reich R, Kloog Y, Kweon YO, Bruck R: Treatment of thioacetamide-induced liver cirrhosis by the ras antagonist, farnesylthiosalicylic acid. J Hepatol. 2004, 41: 235-241. 10.1016\/j.jhep.2004.04.010","journal-title":"J Hepatol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-9-256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:55:24Z","timestamp":1630497324000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-9-256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-9-256","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,22]]},"assertion":[{"value":"27 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"256"}}